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ABSTRACT 
Binge drinking is a pattern of excessive alcohol consumption related to numerous health 
problems, notably alcohol dependence. Corticotropin-releasing factor (CRF) signaling within the 
ventral tegmental area (VTA) is known to regulate dependence-induced alcohol consumption. It 
remains unclear which receptors regulate binge-like consumption. This study utilized the 
drinking-in-the-dark design to examine how intra-VTA CRF-1 receptor (CRF-1R) antagonism 
and CRF-2R agonism influenced binge-like alcohol drinking. Blockade of CRF signaling, by 
CRF-1R antagonism or CRF-2R autoreceptor activation, reduced binge-alcohol consumption. It 
was also unknown whether CRF-mediated effects were the result of local VTA interneurons or 
projection neurons from other brain regions. Transgene expression of eGFP in the VTA of CRF-
Cre mice confirmed the presence of local CRF interneurons. By confirming the role of CRF 
receptors within the VTA in binge-alcohol consumption and establishing the presence of local 
CRF neurons in the VTA, this study clarifies the CRF-mediated effects on binge-like alcohol 
consumption and identifies a potential new mechanism mediating alcohol consumption.  
 
INTRODUCTION 
 
Binge drinking refers to a pattern of excessive alcohol consumption that generates a 
blood alcohol concentration (BEC) of 0.08 grams percent or above in a 2-hr period (National 
Institute on Alcohol Abuse and Alcoholism, 2004). This pattern of drinking is related to a 
number of health problems including high blood pressure, liver disease, neurological damage, 
and often leads to alcohol dependence. Therefore, it is important to examine the neurobiological 
mechanisms that govern the excessive alcohol consumption. 
One such area of investigation includes corticotropin-releasing factors and their role in 
the regulation of alcohol consumption. Corticotropin-releasing factor (CRF) is one member of 
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this peptide family that also includes urotensin, urocortin, and sauvagine. The role of CRF in 
alcohol intake has recently been established. CRF is a 41-amino acid peptide that is generally 
released in response to stress. Although mainly produced in the hypothalamus, CRF is also 
synthesized and secreted by other areas of the brain such as the central amygdala (CeA) and bed 
nucleus of the stria terminalis (BNST), as well as other peripheral tissues (Society for 
Endocrinology 2013). It is important to distinguish between the two CRF receptor subtypes, 
CRF-1 receptor (CRF-1R) and CRF-2 receptor (CRF-2R). While CRF-1R tends to be a 
postsynaptic receptor, CRF-2R is generally referred to as a presynaptic auto- or hetero-receptor 
regulating presynaptic release (Hoare et al., 2005).  
While CRF is most commonly associated with responses to stress and anxiety, it has also 
been implicated in regulating a number of alcohol related behaviors. For example, it has been 
shown that long-term alcohol intake and alcohol dependence are correlated with enhanced 
function of CRF, specifically within the CeA (Funk et al., 2006). In addition, it has been proven 
that intra-amygdalar administration of CRF receptor antagonists reduces alcohol intake after a 
period of abstinence in dependent rats (Valdez et al., 2002). It was previously believed that the 
CRF system did not significantly modulate alcohol intake in nondependent animals, leading to 
the conjecture that neuroadaptations within the CRF system develop over an extended time 
period, leading to alcohol dependence (Koob, 2003, 2009). However, recent data suggests that 
the CRF system is recruited at a much earlier stage, specifically prior to alcohol dependence 
(Lowery-Gionta et al., 2012). A number of studies have demonstrated this effect. Initially, it was 
shown that intracerebroventricular (i.c.v.) administration of a variety of CRF receptor 
compounds attenuated binge-like alcohol consumption (a model of non-dependant alcohol 
drinking). Specifically, the administration of CRF-1 antagonist decreased binge-like 
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consumption, and infusion of urocortin, a CRF-2 agonist, also reduced binge-like alcohol intake 
(Lowery et al., 2010). 
While these studies have shown that the ability of CRF receptors to modulate binge-
drinking behavior, it remains unknown which specific sites in the brain are responsible for 
modulating this behavior. A recent study performed by Lowery-Gionta et al., (2012) 
demonstrated that after binge-like alcohol consumption both the CeA and the ventral tegmental 
area (VTA) showed increased CRF immunoreactivity, and thus were two such sites that are 
likely to be involved. The authors further explored the role of CRF in CeA in binge-like drinking 
by implanting bilateral cannulae aimed at the CeA, and demonstrated intra-CeA injections of 
antalarmin, a CRF-1 receptor antagonist, reduced binge-drinking (Lowery-Gionta et al., 2012). 
While this study focused on the CeA, a separate study explored the role of CRF-1R signaling in 
the VTA in relation to binge drinking. Following similar procedures as the CeA study, this 
experiment implanted bilateral cannulae aimed at the VTA and showed that intra-VTA injections 
of a different CRF-1 antagonist (CP-154,526) reduced binge-drinking in the animals (Sparta et 
al., 2013). The purpose of the present study was to verify the role of CRF-1 receptors in binge-
alcohol drinking in the VTA, and determine a functional role for the CRF-2 receptor. This study 
differs from previous experiments because it utilizes antalarmin as the CRF-1 antagonist in the 
VTA instead of CP-154,526. The use of a different drug is an important distinction because each 
drug possesses a different degree of affinity towards the CRF receptors. The secondary aspect of 
this study was to explore whether or not activating the CRF-2 receptor similarly reduces binge-
drinking behavior, with the hope of further characterizing the role of CRF receptors as they 
pertain to binge-drinking behavior. The study was divided into two parts: Experiment 1 explored 
the effects of CRF-1 antagonist in the VTA while Experiment 2 examined CRF-2 receptor 
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agonism and its relation to binge-drinking behavior. An additional pilot experiment was 
performed to explore the possibility that there are local CRF neurons mediating CRF release and 
influencing alcohol drinking behavior within the VTA, rather than the purported afferent 
projections from other brain regions to the VTA.  
 
MATERIALS AND METHODS 
 
Animals 
C57BL/6J mice (Jackson Labs) were used in Experiments 1 & 2, while CRF-Cre 
transgenic mice (mice who express the exogenous Cre-recombinase selectively only in CRF 
expressing cells) were used for Experiment 3. All mice were approximately 10-12 weeks old at 
the beginning of the study. The mice were housed in individual cages with standard rodent chow 
available at all times. Water was available at all times except when animals were given access to 
alcohol. The rooms in which the mice were housed were maintained at 22° C and on a 12-hr 
light/dark cycle (lights off at 0800). All procedures were carried out in accordance with 
guidelines set by the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals and were approved by the University of North Carolina Institutional Animal Care and 
Use Committee. 
Drugs/Reagents 
Alcohol solutions (20% v/v) were prepared with tap water and 95% ethyl alcohol. 
Antalarmin (42 pmol/0.5 ul; CRF-1 receptor antagonist; (Tocris) was dissolved in 10% DMSO 
(in sterile 0.9% NaCl). Urocortin-3 (Ucn3; 24 & 60 pmol/0.4 ul; CRF-2 receptor agonist) was 
dissolved in 50% DMSO (in sterile 0.9% NaCl, per suppliers recommendations; GenScript). 
Animals were anesthetized for surgical implantation of intra-VTA cannulae with a ketamine (100 
mg/kg)-xylazine (10 mg/kg) cocktail (IP).  Additionally, intra-VTA administration of AAV8-
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hSYN-DIO-eGFP, a Cre-dependent adeno-associated virus with a double inverted open reading 
frame that in the presence of Cre-recombinase in CRF neurons of CRF-Cre mice will cause the 
transcription and subsequently the expression of the enhanced green fluorescent protein (eGFP) 
only in CRF neurons of CRF-Cre mice.    
Drinking-in-the-Dark Procedure 
Alcohol intake was regulated using 4 day drinking-in-the-dark procedure. This procedure 
is optimized to promote binge drinking and generate BECs greater than 80 mg/dl (Rhodes et al., 
2005, 2007; Sparta et al., 2008; Lowery et al., 2010). Three hours into the dark cycle, animals 
were given access to a 20% alcohol solution in their home-cage. Days 1-3 consisted of a 2-hour 
drinking session during which water bottles were removed and replaced with 20% alcohol bottles. 
After 2 hours, alcohol bottles were replaced with water bottles. The same procedure was 
followed for Day 4 except that alcohol bottles were available for 4 hours, this was considered the 
binge test day. All pharmacological manipulations were performed approximately an hour before 
bottles were placed on the cages. Additionally, approximately 10 microliters of tail blood 
samples were collected from each animal immediately after the binge on the test day in order to 
determine the BECs using the Analox Analyzer (Analox Instruments). 
Cannula Placement Verification  
For Experiment 1 & 2, animals were injected with an overdose of ketamine/xylazine and 
infused with Alcian blue dye into the cannulae aimed at the VTA to verify placements. Animals 
were then immediately transcardially perfused with ice-cold 0.1M phosphate buffered saline 
(PBS), followed by 4% paraformaldehyde (in 0.1M phosphate buffer). Brain tissue was then 
extracted, post-fixed in 4% paraformaldehyde for 24 hrs, and sliced on a vibratome (Leica 
Instruments). Forty micron slices were mounted on slides and counterstained with Nuclear Fast 
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Red dye, and visualized on a Nikon-1000 microscope to verify accurate cannulae placement. 
Any animals with missed placements were removed from analyses.   
For Experiment 3, animals were allowed to recover in their homecages for approximately 
3 weeks following surgery to allow for sufficient transduction of the viral vector and expression 
of eGFP. Animals were then injected with an overdose of ketamine/xylazine, and transcardially 
perfused as described above. Tissue was sliced and mounted, and the expression of Cre-induced 
eGFP in VTA CRF neurons was visualized on an EVOS FL microscope (Life Technologies).  
RESULTS 
 
Experiment 1:  
 
Intra-VTA Antalarmin. An independent samples t-test revealed that intra-VTA antalarmin 
significantly reduced alcohol consumption on the binge test day (t(30) = 4.154, p = 0.0002). 
While alcohol consumption was significantly reduced, this reduction was not reflected in 
corresponding BECs (t(30) = 1.238, p = 0.2253). The ability of intra-VTA antalarmin to reduce 
alcohol consumption was reinforcer specific, as it did not reduce binge-like consumption of a 
10% sucrose solution (t(23) = 0.5909, p = 0.5603 - using Welch’s correction for unequal 
variances). See Figure 1.  
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Figure 1. The effects of intra-VTA antalarmin (1.0ug/0.5ul) on binge-like alcohol consumption 
(A), corresponding BECs (B), and sucrose consumption (C). Intra-VTA antalarmin significantly 
reduced binge-like alcohol consumption on the binge test day (* p < 0.001) and there was a trend 
toward a reduction in corresponding BECs. Intra-VTA antalarmin did not, however, reduce 
binge consumption of a 10% sucrose solution, demonstrating this effect was specific to alcohol, 
not other calorie-rich reinforcers.  
 
Experiment 2: 
 
Intra-VTA Urocortin 3. An independent samples t-test revealed that intra-VTA infusion of 24 
pmol Urocortin 3 did not significantly reduce, and in fact appears to cause a small, but 
insignificant increase in alcohol consumption on the binge test day (t(17) = 0.9400, p = 0.3604). 
A second dose of Urocortin 3 (60 pmol) was tested, and an independent samples t-test revealed 
that this dose of Urocortin 3 did significantly reduce binge-like alcohol consumption (t(17) = 
2.479, p = 0.0239), but there was only a trend toward a significant decrease in blood ethanol 
concentrations (t(17) = 1.113, p = 0.2812). Intra-VTA Urocortin3 administration did not 
decrease binge consumption of a 10% sucrose solution (t(17) = 0.0943, p = 0.9260), indicating 
this effect was specific to alcohol. See Figure 2.  
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Figure 2. The effects of intra-VTA Urocortin 3 (24 pmol or 60 pmol/0.4ul) on binge-like alcohol 
consumption (A & B, respectively). Intra-VTA Urocortin 3 at the 60 pmol, but not 24 pmol, dose 
significantly reduced binge-like alcohol consumption on the binge test day (p < 0.05) and there 
was a trend toward a reduction in corresponding BECs (C). Intra-VTA Urocortin 3 did not, 
however, reduce binge consumption of a 10% sucrose solution; demonstrating effect was 
specific to alcohol, not other calorie-rich reinforcers (D).   
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Experiment 3: 
 
The brain tissues of CRF-Cre animals were visualized using an EVOS FL microscope. 
Expression of the eGFP protein can only occur in presence of Cre-recombinase, which is 
localized to CRF neurons, thus if neurons in the VTA express GFP they are CRF expressing 
neurons localized to the VTA, i.e., not afferent projections into the VTA as the AAV8 serotype is 
an anterograde viral vector that is taken up by the soma. Photomicrographs at 20x magnification 
of the VTA revealed a number of eGFP expressing cell bodies within the VTA. This confirms 
that there are local CRF producing neurons in this region. These neurons may be responsible for 
regulating CRF-mediated changes in the consumption of alcohol. Figure 3 illustrates these eGFP 
neurons in the VTA.  
 
 
 
Figure 3. These are representative images of Cre-recombinase mediated eGFP expression in 
CRF neurons of the VTA (20x magnification).  
 
 
DISCUSSION 
 
According to several recent studies, CRF has been associated with regulating a several 
alcohol behaviors. Notably, it has been shown that extended periods of alcohol consumption and 
long term dependence are directly related to enhanced function of CRF, specifically within the 
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CeA (Funk et al., 2006). It has also been shown that intra-amygdalar injection of CRF receptor 
antagonists reduces alcohol intake after a period of abstinence in dependent rats (Valdez et al., 
2002). It was previously hypothesized that the CRF system did not significantly regulate alcohol 
consumption in nondependent animals, leading to the conjecture that neuroadaptations within the 
CRF system form over an extended period of time, leading to alcohol dependence (Koob, 2003, 
2009). Recent data, however, suggests that the CRF system is recruited at a much earlier stage, 
specifically prior to alcohol dependence (Lowery-Gionta et al., 2012). Specifically, this group 
demonstrated that binge-like alcohol consumption increased CRF immunoreactivity in both the 
CeA and VTA, indicating that CRF signaling might be important in regulating binge-like alcohol 
consumption (Lowery-Gionta et al., 2012). This group further went on to that CRF signaling via 
CRF-1 receptors in the CeA modulated binge like alcohol consumption by showing that 
blockade of CRF-1 receptors decreases alcohol consumption. The goal of the present set of 
studies was to further explore the role of intra-VTA CRF signaling in binge alcohol consumption.  
The first experiment supports the conjecture that the injection of intra-VTA antalarmin, a 
CRF-1 receptor antagonist, significantly reduces alcohol intake. Furthermore, since the sucrose 
consumption remained unaffected, it can be concluded that the antagonist is reinforcer (alcohol) 
specific. The intra-VTA antalarmin also illustrated a downward trend in the BEC levels of the 
mice. Infusion of intra-VTA urocortin, a CRF-2 agonist, also reduced alcohol consumption.  
Based on previous data from the lab showing evidence of alcohol-induced increases in 
CRF mRNA in the VTA, experiment 2 examined CRF expression in VTA of CRF-Cre mice 
using a Cre-recombinase dependent expression of eGFP. Using this technique we successfully 
demonstrated the eGFP expression in a small population of neurons in the VTA, which we 
hypothesize are CRF interneurons, and potentially might be involved in regulating the CRF-1 
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receptor mediated reduction in alcohol consumption shown in experiment 1. This demonstration 
is also particularly exciting because it has previously been thought that the VTA did not contain 
CRF producing cells and only received CRF via neurons projecting from areas like the CeA and 
BNST. Thus, we have confirmed that there appear to be local CRF producing neurons in the 
VTA and further studies will serve to determine if these neurons are responsible for mediating 
the CRF-related changes in alcohol intake.   
In order to fully characterize the role of CRF signaling in the VTA in binge-like alcohol 
consumption, future studies are planned to investigate CRF-1 agonism and CRF-2 antagonism. 
This will allow for a complete pharmacological understanding of the CRF system and its relation 
to binge-like alcohol consumption.  Additionally, in order to understand the role of endogenous 
CRF signaling, we will utilize the designer receptors activated by designer drugs (DREADDs) in 
CRF-Cre mice so that we can selectively activate and inhibit CRF neurons specifically within the 
VTA in order to determine whether local CRF interneurons are responsible for the regulation of 
binge-like drinking behavior. The inability of these neurons to exert an effect on alcohol 
consumption would indicate that projection CRF neurons, possibly from the CeA or BNST, 
might regulate this effect.  
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